Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Rhythm Pharmaceuticals Inc (RYTM)

283 + Investors. Track Smart Money conviction in RYTM. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +10
Streak
3Q ▲
Buyers last Q
54%

Smart Money Signals — RYTM

Based on 284 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added RYTM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
284 hedge funds hold RYTM right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +25% more funds vs a year ago

fund count last 6Q
+56 new funds entered over the past year (+25% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 54% buying

165 buying142 selling
Last quarter: 165 funds bought or added vs 142 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new RYTM position: 32 → 54 → 57 → 63. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

44% of holders stayed for 2+ years

■ 44% conviction (2yr+) ■ 27% medium ■ 29% new
125 out of 284 hedge funds have held RYTM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -3%, value -21%

Value
-20%
Shares
-2%
Last quarter: funds added -3% more shares while total portfolio value only changed -21%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📈

Growing discovery — still being found

48 → 32 → 54 → 57 → 63 new funds/Q
New funds entering each quarter: 32 → 54 → 57 → 63. A growing number of institutions are discovering RYTM each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 55% veterans vs 33% newcomers

■ 55% veterans ■ 12% 1-2yr ■ 33% new
Entry-cohort mix of 289 holders: 159 (55%) are 2+ year veterans, 36 entered 1–2 years ago, and 94 (33%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 33% AUM from major funds

33% from top-100 AUM funds
52 of 283 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — RYTM

In 2026 Q1, 165 hedge funds were net buyers of RYTM (63 opened a new position, 102 added to an existing one), while 142 reduced or exited (89 trimmed, 53 sold completely) — a 54% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 33% of total institutional value in RYTM is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +10 funds (more new holders than closures). Total institutional holders: 284.

Hedge Fund Ownership: RYTM

How many hedge funds hold RYTM — quarterly history vs. share price
Quarterly hedge fund ownership of RYTM vs. share price

Market Analysis: RYTM

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: RYTM

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Rhythm Pharmaceuticals Inc (RYTM) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much RYTM has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 77d ago
RYTM
+3.6%
XLV
+4.2%

RYTM outperformed XLV by -0.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 32d ago
RYTM
-0.5%
XLV
+5.3%

Since the filing became public, RYTM outperformed XLV by -5.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

24 top-rated funds 3 high-conviction
Consensus
6.1
/ 10
breadth
×
Elite
3.2
/ 10
conviction
Hedge Fund Positioning: RYTM
283 + Investors

Track Smart Money conviction in RYTM. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 283 274 3.28%
13F Shares 72M 74M -2.58%
Total Value $6.13B $7.72B -20.62%
New Positions 62 57 +5
Increased Positions 100 102 -2
Closed Positions 53 42 +11
Reduced Positions 88 89 -1
Total Calls 3 3 -
Total Puts 3 2 50.0%
PUT/CALL Ratio 1.0 0.67 Neutral

Statistics: RYTM

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

283 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RYTM. Verified SEC 13F-HR filings.

QUARTER:
Top 25 RYTM holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Checkpoint Capital L.P. 38.30% 1,227,200 $106.7M
2 Ra Capital Management, L.P. 6.14% 6,666,837 $579.8M
3 NEXTBio Capital Management LP 5.09% 126,078 $11.0M
4 Perceptive Advisors LLC 4.04% 2,373,795 $206.4M
5 Rock Springs Capital Management LP 3.54% 689,748 $60.0M
6 Nan Fung Group Holdings Ltd 3.52% 49,120 $4.3M
7 Baker BROS. Advisors LP 2.80% 5,604,483 $487.4M
8 Silverarc Capital Management, LLC 2.72% 306,000 $26.6M
9 Integral Health Asset Management, LLC 2.50% 600,000 $52.2M
10 Logos Global Management LP 1.95% 450,000 $39.1M
11 Exome Asset Management LLC 1.83% 40,581 $3.5M
12 Siren, L.L.C. 1.75% 725,511 $63.1M
13 Sofinnova Investments, Inc. 1.49% 450,096 $39.1M
14 Blue Owl Capital Holdings LP 1.44% 61,455 $5.3M
15 PFM Health Sciences, LP 1.08% 136,621 $11.9M
16 ADAR1 Capital Management, LLC 1.08% 211,450 $18.4M
17 Braidwell LP 0.90% 310,628 $27.0M
18 AlphaCentric Advisors LLC 0.81% 9,297 $809K
19 Harvest Investment Services, LLC 0.77% 48,468 $4.2M
20 Westfield Capital Management Co LP 0.70% 1,929,123 $167.8M
21 First Light Asset Management, LLC 0.68% 87,181 $7.6M
22 Orbimed Advisors LLC 0.54% 314,100 $27.3M
23 Cornerstone Partners Capital Management, LLC 0.53% 2,462 $214K
24 Polar Capital Holdings Plc 0.50% 1,615,586 $140.5M
25 SummitTX Capital, L.P. 0.45% 165,599 $14.4M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Rhythm Pharmaceuticals Inc (RYTM)

What does the Smart Money Trend signal show for RYTM?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added RYTM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RYTM?

Slight buying edge — 54% buying: Last quarter: 165 funds bought or added vs 142 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for RYTM holders?

Strong quality — 33% AUM from major funds: 52 of 283 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held RYTM?

44% of holders stayed for 2+ years: 125 out of 284 hedge funds have held RYTM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Rhythm Pharmaceuticals Inc (RYTM) following the 2026 Q1 hedge fund 13F filings?

As of today, RYTM has moved -0.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.3% for the XLV sector ETF — an outperformance of -5.8%. Since the quarter end (March 31, 2026), RYTM has gained +3.6% vs +4.2% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →